Nelfinavir: A review of its use in the management of HIV infection

Drugs

Volumn 65, Issue 15, 2005, Pages 2209-2244

  Perry, Caroline M ^a   Frampton, James E ^a   McCormack, Paul L ^a   Siddiqui, M Asif A ^a   Cvetković, Risto S ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; AZITHROMYCIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL; INDINAVIR; LAMIVUDINE; LOPINAVIR; METHADONE; NELFINAVIR; NORETHISTERONE; PHENYTOIN; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIRTH DEFECT; BLOOD TOXICITY; CHILDHOOD DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DYSLIPIDEMIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LEUKOPENIA; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTOSIS; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PREGNANCY; RASH; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NELFINAVIR; PREGNANCY; SALVAGE THERAPY; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 26944450008     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565150-00015     Document Type: Review

References (141)

1. Yazdanpanah Y, Sissoko D, Egger M, et al. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ 2004 Jan; 328 (7434): 249-53
2. Department of Health and Human Services (US). Guidelines for the use of antiretroviral agents in HIV infected agents in HIV-1 infected adults and adolescents [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/ adult/AA_040705.pdf [Accessed 2005 Aug 19]
3. Agouron Pharmaceuticals Inc. Viracept® (nelfinavir mesylate) tablets and oral powder: US prescribing information [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_viracept.pdf [Accessed 2005 Aug 1]
4. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000 Mar; 59 (3): 581-620
5. Gag-Pol processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother 2000 May; 44 (5): 1397-403
6. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988 Jul; 85: 4686-90
7. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996 Feb; 40 (2): 292-7
8. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001 Apr; 45: 1086-93
9. Patick AK, Boritzki TJ, Bloom LA. Activities of human immun-odeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother 1997 Oct; 41 (10): 2159-64
10. Flexner C. HIV-protease inhibitors. N Engl J Med 1998 Apr 30; 338 (18): 1281-92
11. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002 Jul 5; 16 (10): 1331-40
12. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001 Mar 30; 15: 609-15
13. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000 May 10; 283 (18): 2417-26
14. Nunez M, de Mendoza C, Valer L, et al. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations. Med Sci Monit 2002 Sep; 8 (9): CR620-3
15. Clotet B, Ruiz L, Martinez-Picado J, et al. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 2002 Jul; 3 (4): 316-23
16. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004 Jan 1; 189 (1): 51-60
17. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiencey virus type 1 variants isolated from patients treated with the protease inihibitor nelfinavir. Antimicrob Agents Chemother 1998 Oct; 42 (10): 2637-44
18. Manfredi R, Calza L. HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options [letter]. J Acquir Immune Defic Syndr 2002 Jun 1; 30 (2): 258-60
19. Eshleman SH, Krogstad P, Brooks Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 2001 Jun 15; 183: 1732-8
20. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2159-65
21. Gonzalez LM, Brindeiro RM, Aguiar RS, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004 Sep; 48 (9): 3552-5
22. Masquelier B, Droz C, Dary M, et al. R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen. Antimicrob Agents Chemother 2003 Nov; 47 (11): 3623-6
23. Dronda F, Casado JL, Moreno S, et al. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retroviruses 2001 Feb 10; 17 (3): 211-5
24. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13 (2): F23-8
25. MacManus S, Yates P, Elston R, et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18: 651-5
26. MacManus S, Yates P, White S, et al. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen [abstract no. 598 plus poster]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston (MA)
27. Yerly S, Rickenbach M, Popescu M, et al. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Antivir Ther 2001 Sep; 6: 185-9
28. De Luca A, Di Giambenedetto S, Bacarelli A, et al. Genotypic resistance to boosted (fos)amprenavir and lopinavir in clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors [abstract no. P99]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow
29. Elston R, Yates P, Tisdale M, et al. GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype [abstract no. MoOrB1055]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
30. Bristol-Myers Squibb Company. Reyataz® (atazanavir sulfate) capsules prescribing information, 2005 Jun [online]. Available from URL: http://www.bms.com [Accessed 2005 Sep 30]
31. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12 (11): F111-5
32. Duval X, Peytavin G, Albert I, et al. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med 2004 Jul; 5 (4): 307-13
33. Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005 Mar 4; 19 (4): 371-80
34. Dockrell DH, Badley AD, Villacian JS, et al. The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest 1998 Jun; 101 (11): 2394-405
35. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 2000; 16 (6): 559-67
36. Victorino R, Sousa A, Chaves AF. Effects of triple antiretroviral therapy on the expression of Fas antigen in patients with HIV1 infection [abstract no. 31178]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva
37. Badley AD, Parato K, Cameron DW, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999 May; 6 (5): 420-32
38. Chavan SJ, Tamma SL, Kaplan M, et al. Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol 1999 Oct; 93 (1): 24-33
39. Kaufmann G, Zaunders J, Cunningham P, et al. Comparison of immune reconstitution in subjects treated with HAART during primary and chronic HIV-1 infection [abstract no. 345]. 7th Conference Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA)
40. Smith DE, Kaufmann GR, Kahn JO, et al. Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003 Mar; 19: 189-99
41. Roche Products Limited. UK Summary of product characteristics: Viracept (nelfinavir) 250mg film-coated tablets [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2005 Aug 5]
42. Kaeser B, Charoin JE, Gerber M, et al. Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int J Clin Pharmacol Ther 2005 Mar; 43 (3): 154-62
43. Regazzi MB, Seminari E, Villani P, et al. Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile. J Chemother 2001 Oct; 13: 569-74
44. Hsyu P, Petersen C, Pun E, et al. Increased bioavailability of nelfinavir 625 mg tablet and the potential impact on adverse experiences [abstract no. 116 plus poster]. Antivir Ther 2003 Aug 4; 8: L77-8
45. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002 Apr 12; 16: 889-93
46. Ford J, Cornforth D, Hoggard PG, et al. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther 2004 Feb; 9 (1): 77-84
47. Hennessy M, Clarke S, Spiers JP, et al. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther 2004 Feb; 9 (1): 115-22
48. Hsyu PH, Lillibridge JH, Beeby S, et al. Pharmacokinetics of nelfinavir and metabolite M8 in patients with liver impairment after a single oral 750mg dose of viracept. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 337
49. Regazzi M, Maserati R, Villani P, et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005 Feb; 49 (2): 643-9
50. Mirochnick M, Stek A, Acevedo M, et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. J Acquir Immune Defic Syndr 2005 Jun 1; 39 (2): 189-94
51. Bergshoeff AS, Fraaij PLA, van Rossum AMMC, et al. Pharmacokinetics of nelfinavir in chidren: influencing factors and dose implications. Antivir Ther 2003 Jun; 8 (3): 215-22
52. Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004 Sep 1; 39 (5): 736-40
53. Mirochnick M, Bryson Y, Stek A, et al. Pharmacokinetics of nelfinavir and its M8 metabolite in pregnant HIV-infected women and their infants: PACTG 353 [abstract no. 1891]. Pediatr Res 2003 Apr; 53 (Pt 2): 331
54. van Heeswijk RPG, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004 Dec; 76 (6): 588-97
55. Kruse G, Esser S, Stocker H, et al. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Antivir Ther 2005; 10 (2): 349-55
56. Kruse G, Esser S, Stocker H, et al. Tenofovir (TDF) does not impair the steady-state pharmacokinetics of nelfinavir (NFV) in HIV-infected patients [poster A-446]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2004 Oct 30-Nov 2; Washington, DC
57. Boffito M, Pozniak A, Kearney B, et al. Lack of a drug interaction between tenofovir DF and nelfinavir [poster]. 7th Interna-tional Conference on Drug Therapy in HIV; 2004 Nov 14-18; Glasgow
58. Schippers EF, Hugen PWH, den Hartigh J, et al. No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS 2000 Dec 1; 14: 2794-5
59. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003 Mar 7; 17: 638-40
60. Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002 Mar 8; 16: 543-50
61. Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004 Nov; 48 (11): 4306-14
62. Amsden GW, Nafziger AN, Foulds G, et al. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol 2000 Dec; 40 (Pt 2): 1522-7
63. Kurowski M, Molto J, Breske A, et al. Atazanavir (ATV) enhances trough concentrations of nelfinavir (NFV) and its M8 metabolite in a treatment regimen without ritonavir (RTV) [poster 8.2]. 6th International Workshop of Clinical Pharmacology of HIV Therapy; 2005 Apr 28-30; Quebec
64. Stocker H, Kruse G, Arasteh K, et al. Pharmacokinetic interaction between saquinavir/r and nelfinavir in HIV-infected patients [poster A-454]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2004 Oct 30-Nov 2; Washington, DC
65. Saag MS, Tebas P, Sension M, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 2001 Oct 19; 15: 1971-8
66. Walmsley S, Bernistein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002 Jun 27; 346: 2039-46
67. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT Study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004 Jan 1; 35 (1): 22-32
68. Moyle G, Pozniak A, Opravil M, et al. The SPICE Study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. J Acquir Immune Defic Syndr 2000 Feb 1; 23: 128-37
69. Perez G, MacArthur RD, Walmsley S, et al. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials 2004 Jan 28; 5 (1): 7-18
70. Kirk O, Lundgren JD, Pedersen C, et al. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Antivir Ther 2003 Dec; 8 (6): 595-602
71. Murphy RL, Sanne I, Chan P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17: 2603-14
72. Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003 Apr; 8: 163-71
73. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32: 18-29
74. Gartland M, AVANTI Study Group. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther 2001 Jun; 6: 127-34
75. Gathe Jr JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004 Jul 23; 18 (11): 1529-37
76. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002 Jun; 7: 81-90
77. Bernstein B, Kempf D, Moseley M, et al. Lack of resistance to ABT-378/ritonavir (ABT-378/R) observed after 24 weeks of therapy in antiretroviral-naive subjects [abstract no. P325]. Int Cong Drug Therapy HIV. AIDS 2000; 14 Suppl. 4: S110
78. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001 Aug 9; 345: 398-407
79. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 Dec 11; 349 (24): 2293-303
80. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 Dec 11; 349 (24): 2304-15
81. Cooper D, Yeni P. Virological and immunological outcomes at 3 years following initiation of ART with regimens containing a NNRTI or PI or both: the INITIO Trial [abstract no. 165LB]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston (MA)
82. Daniels E, Clotet B, Clax P, et al. Long-term efficacy of nelfinavir, impact on adverse events and lipodystrophy [poster 100]. Antivir Ther 2004; 9 (6): L57
83. Fumaz C, Lopez Aldeguer J, Lozano F, et al. Clinical and psychological impact of prolonged nelfinavir-containing regimens. PSIRENE study [abstract no. P54]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow
84. Gathe J, Chu A, Yuen N, et al. Durability of nelfinavir combination therapy after 4 years: 3-year extension data from Agouron Study 511 [poster LB10]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, Greece
85. Roca B, Gomez CJ, Arnedo A. A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. AIDS 2000 Jan 28; 14: 157-61
86. Smith D, Hales G, Roth N, et al. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clin Trials 2001 Mar 30; 2 (2): 97-107
87. Bahrani A, Oldfield IEC. Substitution of nelfinavir (NV) for indinavir (IV) in patients on combination therapy and the effect on viral loads [abstract no. I-241]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA), 440
88. Trylesinski A, Dohin E, Delmas C, et al. Alleviating protease inhibitor constraints and for a viral load maintained below the limit of quantification for the long term efficacy, tolerance and compliance: the nelfinavir switch solution [abstract no. P114]. AIDS 1998 Nov; 12 Suppl. 4: S45
89. Lefebvre E, Shafran S. Maintenance of virological suppression in patients switched from indinavir (IDV) to nelfinavir (NFV) [abstract no. P62]. AIDS 2000 Oct; 14 Suppl. 4: S34
90. Wensing AMJ, Reedijk M, Richter C, et al. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS 2001 Nov 9; 15: 2191-3
91. Starrett B, Connor S. Maintenance of viral suppression and improvement of metabolic parameters after replacing ritonavir with nelfinavir in a HAART regimen [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA)
92. Knechten H, Lippok B, Knickmann M. Switch from indinavir (IDV) to nelfinavir (NFV) in patients on antiviral therapy with stavudine (d4T) and lamivudine (3TC) [abstract P123]. AIDS 1998 Nov; 12 Suppl. 4: S47
93. Hellinger JA, Cohen CJ, Stein AJ, et al. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy. HIV Clin Trials 2000; 1 (2): 25-8
94. Post J, Williams C. An open label, randomized trial switching nelfinavir dosing from tid to bid: 84 week report [abstract no. TuPeB3224]. 13th International AIDS Conference; 2000 Jul 9-14; Durban, 362
95. Dhingra R, Munsiff A. Twice daily nelfinavir results in greater durability and higher CD4 counts than TID dosing [abstract no. WePeB4118]. 13th International AIDS Conference; 2000 Jul 9-14; Durban, 59
96. Johnson M, Nieto-Cisneros L, Horban A, et al. Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations. HIV Med 2005 Mar; 6 (2): 107-13
97. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delaviridine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000 Nov; 182: 1375-84
98. Hammer SM, Bassett R, Squires KE, et al. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther 2003 Dec; 8 (6): 507-18
99. Perez-Molina JA, Perez Nr R, Miralles P, et al. Nelfinavir plus nevirapine plus two NRTIs as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment. HIV Clin Trials 2001 Jan 28; 2 (1): 1-5
100. Sullivan AK, Nelson MR, Shaw A, et al. Efficacy of a nelfinavir- and nevirapine-containing salvage regimen. HIV Clin Trials 2000 Jul 31; 1: 7-12
101. Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr 1999 Dec 15; 22 (5): 453-60
102. Casado JL, Dronda F, Garcia-Aratia I, et al. Efficacy and tolerability of the combination of nevirapine, nelfinavir and saquinavir after ritonavir or indinavir failure [abstract no. 529]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 112
103. Arrizabalaga J, Iribarren JA, Rodriguez-Arrondo FJ, et al. Salvage therapy with ddI + hydroxyurea (HU) + efavirenz (EFV) + nelfinavir (NFV) in patients who had previously failed indinavir (IDV)/ritonavir (RIT) regimens. 24 weeks follow-up [abstract no. 2206]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), 537
104. Santos J, Palacios R, Ruiz I, et al. Efficacy of nelfinavir as salvage therapy for protease inhibitors failures [abstract no. P65]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; Athens 2001 Oct 28-31, 70
105. Viciana P, Perez R, Hernadez Quero J, et al. NNRTI salvage therapy with nelfinavir in PI naive patients [abstract plus poster 7.4/15]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop; 2003 Oct 25; Warsaw, 57
106. Hall CS, Raines CP, Barnett SH, et al. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999; 13 (10): 1207-12
107. Zolopa A, Tebas P, Gallant J, et al. The efficacy of ritonavir (RTV)/saquinavir(SQV) antiretroviral therapy (ART) in patients who failed nelfinavir (NFV): a multicentre cohort study [abstract no. 2065]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), 527
108. Cavorus A, Thompson CE, Salvato PD. Salvage therapy for antiretroviral failure in HIV+ patients [abstract no. 22402]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 344
109. Center of Drug Evaluation and Research of the US Food and Drug Administration. Clinical review for NDA [online]. Available from URL: http://www.fda.gov/cder/foi/esum/2004/20778se5-022,20779se5-042, 21503se5-001_viracept_clinical_bpca.pdf [Accessed 2005 Aug 19]
110. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002 Apr 1; 34: 991-1001
111. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004 Jun 10; 350 (24): 2471-2480
112. Starr S, Courtney C, Spector S, et al. Combination therapy wtih efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999 Dec 16; 341: 1874-81
113. Starr S, Fletcher C, Spector S, et al. Efavirenz liquid formulations in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002 Jul; 21 (7): 659-63
114. Hoffmann F, Notheis G, Wintergerst U, et al. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection. Pediatr Infect Dis J 2000 Jan; 19: 47-51
115. Resino S, Alvaro-Meca A, de Jose MI, et al. Lopinavir/r versus nelfinavir as salvage therapy [letter]. Pediatr Infect Dis J 2005 Apr; 24 (4): 392-3
116. Rachlis A, Gill M, Baril Jeal. Step-wise intervention for the management of nelfinavir (NFV)-associated diarrhoea [abstract plus poster no. 747]. Antivir Ther 2003; 8 Suppl. 1: S392
117. Heiser CR, Ernst JA, Barrett JT, et al. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care (Chic Ill) 2004 Oct 31; 3 (4): 121-9
118. Huffman FG, Walgren ME. L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals. HIV Clin Trials 2003 Sep 31; 4 (5): 324-9
119. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001 Jul 6; 15: 1275-80
120. Guest JL, Ruffin C, Tschampa JM, et al. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir. Pharmacotherapy 2004 Jun; 24 (6): 727-35
121. Bruno R, Sacchi P, Maiocchi L, et al. Hepatotoxicity and nelfinavir: a meta-analysis. Clin Gastroenterol Hepatol 2005 May; 3 (5): 482-8
122. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004 Mar 15; 189 (6): 1056-74
123. Murphy R, Thiry A, Mancini M, et al. Switch to atazanavir from nelfinavir associated with cholesterol and triglyceride improvement: 12 wk results from BMS AI424-044 [abstract LBPEB9013 plus poster]. 14th International AIDS Conference; Barcelona 2002 Jul 7-12, 38
124. Duncombe C. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir. J Acquir Immune Defic Syndr 2000 May 1; 24: 78-9
125. Grover SA, Coupal L, Gilmore N, et al. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005 Mar 1; 95 (5): 586-91
126. da Silva B, ing M, Cernohous P, et al. Risk factors for body fat composition changes in patients treated with lopinavir/ritonavir or nelfinavir [abstract no. 99]. Antivir Ther 2003 Aug 4; 8: L68
127. Treluyer JM, Morini JP, Dimet J, et al. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002 Dec; 46: 4009-12
128. Lewis RH, Popescu M. Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy. J Acquir Immune Defic Syndr 2000 Apr 1; 23: 355-6
129. Dube M, Zackin R, Parker R, et al. Prospective study of glucose and lipid metabolism in antiretroviral-naive subjects randomized to receive nelfinavir, efavirenz, or both combined with zidovudine+ lamivudine or didanosine+stavudine: A5005s, a substudy of ACTG 384 [abstract no. 74]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA), 2
130. Center for Drug Evaluation and Research for the US Food and Drug Administration. One year post-pediatric exclusivity post-marketing adverse event review: drug use data - nelfinavir mesylate [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b1_06_02_Nelfinavir. pdf [Accessed 2005 Aug 19]
131. Covington DL, Conner SD, Doi PA, et al. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol 2004 Jun; 103 (6): 1181-9
132. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy . AIDS 2005 May 20; 19 (8): 795-9
133. Hitti J, Frenkel L, Stek A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004 Jul; 36 (3): 772-6
134. Baylor M, Gibbs N. Hepatotoxicity during pregnancy: a review of the FDA adverse event reporting system (AERS) database [abstract and poster 944]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco
135. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004 Jul 14; 292 (2): 251-65
136. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004; 39: 609-29
137. The British HIV Association. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2005 [online]. Available from URL: http://www.bhiva.org/guidelines/2005/HIV/index.html [Accessed 2005 Aug 29]
138. The EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003 Jun; 17 Suppl. 2: S3-26
139. Department of Health and Human Services (US). Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/pediatric/PED_032405 [Accessed 2005 Aug 01]
140. Hirsch MS. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003; 37: 113-28
141. Cvetković RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63 (8): 769-802